يعرض 1 - 10 نتائج من 91 نتيجة بحث عن '"Otros calificadores::/uso terapéutico [Otros calificadores]"', وقت الاستعلام: 1.67s تنقيح النتائج
  1. 1

    المساهمون: Gastroenterology & Hepatology, Institut Català de la Salut, [Janssen HLA] Toronto General Hospital, Toronto, Ontario, Canada. Erasmus Medical Center, Rotterdam, Zuid-Holland, The Netherlands. [Hou J] Nanfang Hospital, Southern Medical University, Guangzhou, China. [Asselah T] Université de Paris Cité, INSERM UMR1149, Hôpital Beaujon AP-HP, Clichy, France. [Chan HLY] The Chinese University of Hong Kong, Hong Kong SAR, China. [Zoulim F] Hospices Civils de Lyon and Lyon University & INSERM U1052-Cancer Research Institute of Lyon, Lyon, France. [Tanaka Y] Department of Gastroenterology and Hepatology, Kumamoto University, Kumamoto, Japan. [Buti M] Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERHED del Instituto Carlos III, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Gut. BMJ Publishing Group
    Scientia

    وصف الملف: application/pdf

  2. 2

    المساهمون: Institut Català de la Salut, [Mesa RA] Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA. [Hudgens S, Floden L] Clinical Outcomes Solutions, Tucson, Arizona, USA. [Harrison CN] Guy's and St. Thomas' NHS Foundation Trust, London, UK. [Palmer J] Mayo Clinic, Phoenix, Arizona, USA. [Gupta V] University Health Network, University of Toronto, Toronto, Ontario, Canada. [Fox ML] Servei d’Hematologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Mesa, R A, Hudgens, S, Floden, L, Harrison, C N, Palmer, J, Gupta, V, McLornan, D P, McMullin, M F, Kiladjian, J-J, Foltz, L, Platzbecker, U, Fox, M L, Mead, A J, Ross, D M, Oh, S T, Perkins, A, Leahy, M F, Deheshi, S, Donahue, R, Klencke, B J & Verstovsek, S 2023, ' Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies ', Cancer Medicine . https://doi.org/10.1002/cam4.5799
    Scientia

    وصف الملف: application/pdf

  3. 3

    المساهمون: Institut Català de la Salut, [Mateos-Muñoz B] Hospital Universitario Ramón y Cajal, CIBEREHD, IRYCIS, Universidad de Alcalá, Madrid, Spain. [Buti M, Marcos-Fosch C] Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBEREHD, Barcelona, Spain. [Fernández Vázquez I] Gastroenterology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain. [Hernández Conde M] Gastroenterology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain. [Bernal-Monterde V] Gastroenterology Department, Hospital Miguel Servet, Zaragoza, Spain. [Díaz-Fontenla F] Gastroenterology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  4. 4

    المساهمون: Institut Català de la Salut, [González-Juanatey JR] Cardiology Department, Hospital Clínico Universitario Santiago de Compostela, Centro de investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Santiago de Compostela, Spain. [Górriz JL] Nephrology Department, Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, Spain. [Ortiz A] Nephrology Department, Fundación Jiménez Díaz, Madrid, Spain. [Valle A] Cardiology Department, Hospital La Salud, Valencia, Spain. [Soler MJ] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Facila L] Cardiology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  5. 5

    المساهمون: Institut Català de la Salut, [Sans-Pola C, Danés I, Agustí A] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca de Farmacologia Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Bosch JÀ] Departament de Medicina Interna, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Marrero-Álvarez P] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Cortés J] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  6. 6

    المساهمون: Internal Medicine, Institut Català de la Salut, [Hernando J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Kolarova T] International Neuroendocrine Cancer Alliance, Boston, Massachusetts, USA. [Verslype C] University Hospital Gasthuisberg Leuven, Leuven, Belgium. [Kaltsas G] National and Kapodistrian University of Athens, Athens, Greece. [Houchard A, Gueguen D] Ipsen, Boulogne-Billancourt, France. [De Herder WW] Erasmus MC, Rotterdam, The Netherlands, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Journal of Neuroendocrinology. Wiley-Blackwell Publishing Ltd
    Scientia

    مصطلحات موضوعية: neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos [ENFERMEDADES], Endocrine and Autonomic Systems, Otros calificadores::/uso terapéutico [Otros calificadores], Endocrinology, Diabetes and Metabolism, Pacients - Satisfacció, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Tumors neuroendocrins - Tractament, Somatostatina - Ús terapèutic, Other subheadings::Other subheadings::/drug therapy [Other subheadings], hormonas, sustitutos de hormonas y antagonistas de hormonas::hormonas::hormonas peptídicas::hormonas hipotalámicas::hormonas inhibidoras de la liberación de hormonas hipofisarias::somatostatina [COMPUESTOS QUÍMICOS Y DROGAS], Cellular and Molecular Neuroscience, Endocrinology, SDG 3 - Good Health and Well-being, Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors [DISEASES], terapéutica::farmacoterapia::vías de administración de medicamentos::inyecciones [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Other subheadings::/therapeutic use [Other subheadings], Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Peptide Hormones::Hypothalamic Hormones::Pituitary Hormone Release Inhibiting Hormones::Somatostatin [CHEMICALS AND DRUGS], Therapeutics::Drug Therapy::Drug Administration Routes::Injections [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT]

    وصف الملف: application/pdf

  7. 7

    المساهمون: Institut Català de la Salut, [Moss MH] Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. [Lugogo NL] Division of Pulmonary & Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA. [Castro M] Division of Pulmonary, Critical Care & Sleep Medicine, University of Kansas, Kansas City, KS, USA. [Hanania NA] Section of Pulmonary & Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA. [Ludwig-Sengpiel A] KLB Gesundheitsforschung Lübeck, Lübeck, Germany. [Saralaya D] NIHR PRC, Bradford Institute for Health Research, Bradford, England. [Ojanguren I] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Enfermedades Respiratorias, Barcelona, Catalonia, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  8. 8

    المساهمون: Institut Català de la Salut, [DiSilvestro P] Program in Women's Oncology, Women & Infants Hospital, Providence, RI. [Banerjee S] The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom. [Colombo N] University of Milan-Bicocca and Istituto Europeo di Oncologia IRCCS, Milan, Italy. [Scambia G] Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. [Kim BG] Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. [Oaknin A] Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Disilvestro, P, Banerjee, S, Colombo, N, Scambia, G, Kim, B, Oaknin, A, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G, Gourley, C, Oza, A, González-Martín, A, Aghajanian, C, Bradley, W, Mathews, C, Liu, J, Mcnamara, J, Lowe, E, Ah-See, M, Moore, K

    المصدر: Scientia
    Disilvestro, P, Banerjee, S, Colombo, N, Scambia, G, Kim, B, Oaknin, A, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G S, Gourley, C, Oza, A, González-martín, A, Aghajanian, C, Bradley, W, Mathews, C, Liu, J, Mcnamara, J, Lowe, E S, Ah-see, M & Moore, K N 2022, ' Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.22.01549

    وصف الملف: application/pdf; STAMPA

  9. 9

    المساهمون: Institut Català de la Salut, [Ferrer R] Servicio de Medicina Intensiva, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Soriano A, García-Vidal C] Servicio de Enfermedades Infecciosas, Hospital Clínic de Barcelona, IDIBAPS, Universidad de Barcelona, Spain. [Cantón R] Servicio de Microbiología, Hospital Universitario Ramón y Cajal e Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. [Del Pozo JL] Servicio de Enfermedades Infecciosas y Microbiología Clínica, Universidad de Navarra, Spain. [Garnacho-Montero J] Unidad Clínica Cuidados Intensivos, Hospital Universitario Virgen de la Macarena, Seville, Spain. [Larrosa N] Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  10. 10

    المساهمون: Institut Català de la Salut, [Cree BA] Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA. [Selmaj KW] Center for Neurology, Łódź, Poland and Collegium Medicum, Department of Neurology, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland. [Steinman L] Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, CA, USA. [Comi G] Vita-Salute San Raffaele University and Casa di Cura del Policlinico, Milan, Italy. [Bar-Or A] Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. [Arnold DL] NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, QC, Canada. [Montalbán X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    مصطلحات موضوعية: Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors [CHEMICALS AND DRUGS], Immunoteràpia, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Sphingosine 1-phosphate receptor modulators, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Multiple sclerosis, Ozanimod, Multiple Sclerosis, Relapsing-Remitting, Recurrence, Extension study, Humans, Other subheadings::/therapeutic use [Other subheadings], Sphingosine-1-Phosphate Receptors, acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::factores inmunitarios [COMPUESTOS QUÍMICOS Y DROGAS], Oxadiazoles, Otros calificadores::/uso terapéutico [Otros calificadores], Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis [DISEASES], diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Clinical efficacy, Neurology, Adverse events, Indans, enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES], Avaluació de resultats (Assistència sanitària), Neurology (clinical), Esclerosi múltiple - Tractament, Follow-Up Studies

    وصف الملف: application/pdf